Edition:
United Kingdom

People: Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

0.62USD
20 Aug 2019
Change (% chg)

$-0.02 (-3.12%)
Prev Close
$0.64
Open
$0.62
Day's High
$0.65
Day's Low
$0.62
Volume
30,267
Avg. Vol
33,625
52-wk High
$1.32
52-wk Low
$0.55

Bruder, Scott 

Dr. Scott P. Bruder, M.D. Ph.D. is Bellerophon Therapeutics, Inc. He served as the Chief Medical and Scientific Officer of Stryker Corporation from 2013 until 2014, and from 2007 until 2013 he served as the Chief Science and Technology Officer for Becton, Dickinson and Company. Dr. Bruder has also held a number of senior executive and scientific roles at Johnson & Johnson, Anika Therapeutics and Osiris Therapeutics. He is a magna cum laude graduate from Brown University with a Sc.B. in Biology, and a graduate of Case Western Reserve University School of Medicine, where he simultaneously earned an M.D. and a Ph.D. in stem cell biology. He obtained additional clinical training at Albert Einstein Medical Center and the University of Pennsylvania. He is currently an adjunct Professor of Biomedical Engineering at Case, where he previously served as an adjunct faculty member in the Department of Orthopaedic Surgery for thirteen years. Dr. Bruder recently served on an FDA Advisory Committee for Cellular, Tissue and Gene Therapies, and he continues to serve on several Academic Advisory Boards for biomedical engineering at leading universities.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --